2008-2011 华中科技大学 内科学（血液病） 博士

2003-2007 华中科技大学 内科学（血液病） 硕士

1997-2002 华中科技大学（同济医科大学） 临床医学 学士

2024-今 中国医学科学院血液病医院（中国医学科学院血液学研究所）

2002-2024 华中科技大学同济医学院附属同济医院

1. IL-10在免疫效应细胞相关血液毒性中的致病机制及靶向干预策略研究，国家自然科学基金面上项目，82670283，主持，2027/01-2030/12

2. 免疫-胶质细胞互作诱发免疫效应细胞相关神经毒性综合征的机制和干预，国家自然科学基金面上项目，82470194，主持，2025/01-2028/12

3. 系统揭示和干预 CAR-T 长期生存的限制因素及机制，中国医学科学院创新工程医学健康领军科技人才养募专项，2024-I2M-3-021，主持，2024/10-2029/09

4. T细胞淋巴瘤/白血病进展演变机制及个体化精准诊疗体系——创新细胞治疗开拓T细胞淋巴瘤/白血病的治疗新模式（课题四），国家重点研发计划，2022YFC2502604，主持，2022/11-2025/12

5. 白介素10和白介素18诱发噬血细胞性淋巴组织细胞增生症的机制研究与干预策略，国家自然科学基金面上项目，82070211，主持，2021/01-2024/12

6. 靶向CD93的嵌合抗原受体修饰T细胞疗法治疗携带MLL重排的急性髓系白血病的临床前研究，国家自然科学基金面上项目，81670152，主持，2017/01-2020/12

7. 应用条件性MLL-AF6基因敲入小鼠研究DNA甲基化在MLL白血病转化中的作用，“863”计划生物医药领域青年科学家专题项目，2014AA020532，主持，2014/01-2016/12

8. 利用基因组编辑技术TALEN研究FLT3-ITD突变导致AML进展的分子机制，国家自然科学基金青年基金，81200380，主持，2013/01-2015/12

1. Ye S^#, Xu Q^#, Xu Y, Lu H, Liu Z, Guo J, Li Y, Wang W, Ran J, Zhu X, Zhu D, Wu W, Yang Z, Gu S, Li F, Qiu L, Puré E, Bhoj VG, Huang L^*, Xiong W^*, Zhang Z^*. Bispecific antibody engineered extracellular vesicles redirect T cells to prevent postoperative epidural fibrosis. Nat Commun. 2026 Jun 27;17(1):8054.

2. Cheng J^#, Hu X^#, Dai Z^#, Zeng Y, Jin J, Mu W, Wei Q, Jia X, Liu J, Xie M, Luo Q, Hu G, Wang G, Zhu X, Zhou J, Xiao M, Wang J^*, Tan T^*, Huang L^*. Targeting intracellular LMP2 with costimulatory signal-armed antibody-like TCR T cells. JCI Insight. 2025 May 22;10(10):e178572.

3. Cheng Y^#, Zhang J^#, Mu W^#, Ye S, Cheng J, Zhu L, Wang G, Cao Y, Li D, Hu G^*, Huang L^*, Wang J^*, Zhou J. Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Mol Ther. 2025 Apr 2;33(4):1535-1551.

4. Li Z^#*, Zhao L^#, Zhang Y, Zhu L, Mu W, Ge T, Jin J, Tan J, Cheng J, Wang J, Wang N, Zhou X, Chen L, Chang Z, Liu C, Bian Z, Liu B^*, Ye L^*, Lan Y^*, Huang L^*, Zhou J. Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients. Cell Rep. 2023 Oct 31;42(10):113263.

5. Tang Y^#, Xu Q^#, Luo H^#, Yan X, Wang G, Hu L, Jin J, Witte DP, Marsh RA, Huang L^*, Huang G^*, Zhou J^*. Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis-like hyperinflammation and enhanced myelopoiesis. J Allergy Clin Immunol. 2022 Nov;150(5):1154-1167.

6. Wei J^#, Xiao M^#, Mao Z^#, Wang N, Cao Y, Xiao Y, Meng F, Sun W, Wang Y, Yang X, Chen L, Zhang Y, Zhu H, Zhang S, Zhang T, Zhou J^*, Huang L^*. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Target Ther. 2022 Apr 11;7(1):101.

7. Cao W^#, Wei J^#, Wang N, Xu H, Xiao M, Huang L, Cao Y, Li C, Xiao Y, Gu C, Zhang S, Li D, Zhang Y, Zhang T, Zhou J^*, Huang L^*. Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy. Blood. 2020 Jul 23;136(4):516-519.

8. Wang N^#, Hu X^#, Cao W, Li C, Xiao Y, Cao Y, Gu C, Zhang S, Chen L, Cheng J, Wang G, Zhou X, Zheng M, Mao X, Jiang L, Wang D, Wang Q, Lou Y, Cai H, Yan D, Zhang Y, Zhang T, Zhou J^*, Huang L^*. Efficacy and Safety of CAR19/22 T-cell Cocktail Therapy in Patients with Refractory/Relapsed B-Cell Malignancies. Blood. 2020 Jan 2;135(1):17-27.

9. Huang L^#, Liu D^#, Wang N^#, Ling S^#, Tang Y^#, Wu J, Hao L, Luo H, Hu X, Sheng L, Zhu L, Wang D, Luo Y, Shang Z, Xiao M, Mao X, Zhou K, Cao L, Dong L, Zheng X, Sui P, He J, Mo S, Yan J, Ao Q, Qiu L, Zhou H, Liu Q, Zhang H, Li J, Jin J, Fu L, Zhao W, Chen J, Du X, Qing G, Liu H, Liu X, Huang G, Ma D, Zhou J^*, Wang QF^*. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018 Feb;28(2):172-186.

10.Tang YT^#, Wang D^#, Luo H^#, Xiao M, Zhou HS, Liu D, Ling SP, Wang N, Hu XL, Luo Y, Mao X, Ao QL, Huang J, Zhang W, Sheng LS, Zhu LJ, Shang Z, Gao LL, Zhang PL, Zhou M, Zhou KG, Qiu LG, Liu QF, Zhang HY, Li JY, Jin J, Fu L, Zhao WL, Chen JP, Du X, Huang G, Wang QF, Zhou JF^*, Huang L^*. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J. 2017 Dec 21;7(12):660.